ConCallIQ
Go Pro
ALKEM Diversified 15 May 2026

Alkem Laboratories Limited — Q4 FY26

Alkem delivered a strong Q4 FY26 with revenue of ₹3,633 crore (+14.6% YoY) and EBITDA of ₹517.4 crore (+32.2% YoY), resulting in an EBITDA margin of 14.24% (+184 bps YoY).

bullish high
Compare with...
Revenue ₹3,603 Cr +14.6%
EBITDA ₹517 Cr +32.2%
PAT ₹251 Cr
EBITDA Margin 14% +184bps
Duration 48 min
Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Geopolitical supply chain disruptions

Rising logistics costs, API and packaging material prices due to geopolitical tensions could pressure margins.

high · management_commentary
R

US pricing erosion and competition

Base business in US faces value erosion; new launches may not fully offset if competition intensifies.

medium · analyst_question
R

Trade generic growth slowdown

Trade generic business grew only ~4% due to restructuring; recovery may be slower than expected.

medium · data_observation
R

CEO transition uncertainty

CEO Dr. Vikas Gupta is leaving; new CEO search is ongoing, which could cause temporary strategic drift.

medium · analyst_question